Exscientia Performance dei guadagni passati
Il passato criteri di controllo 0/6
Exscientia's earnings have been declining at an average annual rate of -44.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 4% per year.
Informazioni chiave
-44.5%
Tasso di crescita degli utili
-19.3%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.0% |
| Tasso di crescita dei ricavi | -4.0% |
| Rendimento del capitale proprio | -43.8% |
| Margine netto | -616.5% |
| Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others
Aug 08Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation
Jul 17
Exscientia: Too Much Pessimism
Jun 10Exscientia: Drug Discovery Platform Attracting Partners And Cash
May 22Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)
Feb 26Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?
Jan 11Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 12New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)
Aug 31We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Aug 25Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher
Jul 21Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans
Apr 22We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Dec 30The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts
Aug 31Exscientia: Using AI To Power Drug Development
Aug 15Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth
May 29Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline
Apr 12Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts
Jan 09Ripartizione dei ricavi e delle spese
Come Exscientia guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 21 | -130 | 43 | 111 |
| 31 Mar 24 | 20 | -129 | 38 | 119 |
| 31 Dec 23 | 20 | -146 | 45 | 128 |
| 30 Sep 23 | 24 | -144 | 42 | 135 |
| 30 Jun 23 | 22 | -148 | 41 | 139 |
| 31 Mar 23 | 26 | -141 | 42 | 139 |
| 31 Dec 22 | 27 | -119 | 38 | 129 |
| 30 Sep 22 | 25 | -100 | 35 | 112 |
| 30 Jun 22 | 36 | -69 | 34 | 88 |
| 31 Mar 22 | 29 | -59 | 29 | 63 |
| 31 Dec 21 | 27 | -49 | 26 | 44 |
| 30 Sep 21 | 27 | -36 | 21 | 29 |
| 30 Jun 21 | 10 | -39 | 14 | 19 |
| 31 Mar 21 | 13 | -24 | 8 | 13 |
| 31 Dec 20 | 10 | -22 | 6 | 11 |
| 31 Dec 19 | 9 | -6 | 5 | 7 |
Guadagni di qualità: EXAI is currently unprofitable.
Margine di profitto in crescita: EXAI is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: EXAI is unprofitable, and losses have increased over the past 5 years at a rate of 44.5% per year.
Accelerare la crescita: Unable to compare EXAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: EXAI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendimento del capitale proprio
ROE elevato: EXAI has a negative Return on Equity (-43.78%), as it is currently unprofitable.